A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy Participants
Completed · Phase 1 · NCT04451408
Conditions: Alzheimer Disease, Healthy
At a glance
- Research payments reported, 2025
- $2.7M
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 139
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY3372993 (drug), Placebo (drug)
- Dates
- Started 2020-07-07; completion 2024-11-18
- Results posted
- Not yet
The main purpose of this study is to evaluate the safety and tolerability of LY3372993 in participants with AD, non-Japanese, and Japanese healthy participants who are of first-generation Japanese origin. The study will also investigate how much LY3372993 gets into the bloodstream and will test the effects of LY3372993. The study will be conducted in two parts. The part A includes participants with AD and part B includes healthy participants. Participation could last up to about 61 weeks and may include up to 31 visits to the study center.
From ClinicalTrials.gov, last updated 2025-03-28. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $2.7M in research payments for this study in 2025 (5 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Alexander White, MD Family Medicine · Daytona Beach, FL
- Jeffrey A. Norton, M.D. Pain Medicine · Lawrence, MA
- Gene W. Voskuhl, MD Infectious Disease · Sherman, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Covance Clinical Research LP Dallas $2.6M
- Progressive Medical Concepts LLC $62,923
- Charter Research LLC $13,459
- $180
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.